The program will support Johns Hopkins' research into saliva testing and diagnostics and will help GBS form its commercialization strategy for two saliva-based tests.
For the first time, WHO's essential diagnostics list includes tests that it recommends should also not be supplied because they are unreliable, among other reasons.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.